Drawing for Serial No. 79279432

USPTO serial 79279432

Serial No. 79279432

Reviewed by CopyMark Law Group

Reg. 6138796Status 404
Filing date
Status date
Registration date
Sep 1, 2020
Examiner
CARR, PATRICK C
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with Serial No. 79279432?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III Tepper & Eyster, PLLC3724 BENSON DRRALEIGH, NC 27609UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthmaSECTION 70 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 24, 2026DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED—
Sep 24, 2026DETHDEATH OF INTERNATIONAL REGISTRATION—
Oct 9, 2025RNWLINTERNATIONAL REGISTRATION RENEWED—
Sep 1, 2025REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Jan 23, 2021FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Dec 31, 2020FICSFINAL DISPOSITION NOTICE SENT TO IB—
Dec 31, 2020FIMPFINAL DISPOSITION PROCESSED—
Dec 1, 2020FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Sep 1, 2020R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 16, 2020NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 16, 2020PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 27, 2020NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 12, 2020CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 8, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 8, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 8, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 6, 2020CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 6, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 6, 2020ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
May 6, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 6, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 6, 2020COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Apr 24, 2020RFNTREFUSAL PROCESSED BY IB—
Mar 28, 2020RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 28, 2020RFRRREFUSAL PROCESSED BY MPU—
Mar 10, 2020RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Mar 9, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 5, 2020DOCKASSIGNED TO EXAMINER—
Mar 3, 2020MAFRAPPLICATION FILING RECEIPT MAILED—
Feb 27, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 24, 2020LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Feb 20, 2020SDRCSN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB—

Frequently asked questions

Related guidance